|
Name |
Kigelianolide
|
Molecular Formula | C27H34O10 | |
IUPAC Name* |
methyl (2S)-2-[(1S,3S,4R,8S,9S,12R,13R,14S,17S,19S)-8-(furan-3-yl)-4,17,19-trihydroxy-9,13,15-trimethyl-6-oxo-2,7-dioxahexacyclo[13.3.1.03,12.03,18.04,9.013,17]nonadecan-14-yl]-2-hydroxyacetate
|
|
SMILES |
C[C@@]12CC[C@@H]3[C@]4([C@H](C5(C[C@@]4(C6[C@@]3([C@]1(CC(=O)O[C@H]2C7=COC=C7)O)O[C@@H]6[C@H]5O)O)C)[C@@H](C(=O)OC)O)C
|
|
InChI |
InChI=1S/C27H34O10/c1-22-11-25(32)18-16(19(22)30)37-27(18)13(24(25,3)17(22)15(29)21(31)34-4)5-7-23(2)20(12-6-8-35-10-12)36-14(28)9-26(23,27)33/h6,8,10,13,15-20,29-30,32-33H,5,7,9,11H2,1-4H3/t13-,15+,16+,17+,18?,19-,20+,22?,23+,24+,25+,26-,27+/m1/s1
|
|
InChIKey |
IYYAUMDPBYPGGG-HFALMCGGSA-N
|
|
Synonyms |
Kigelianolide
|
|
CAS | NA | |
PubChem CID | 102592682 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 518.6 | ALogp: | -0.1 |
HBD: | 4 | HBA: | 10 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 156.0 | Aromatic Rings: | 7 |
Heavy Atoms: | 37 | QED Weighted: | 0.43 |
Caco-2 Permeability: | -5.497 | MDCK Permeability: | 0.00003250 |
Pgp-inhibitor: | 0.107 | Pgp-substrate: | 0.985 |
Human Intestinal Absorption (HIA): | 0.766 | 20% Bioavailability (F20%): | 0.972 |
30% Bioavailability (F30%): | 0.982 |
Blood-Brain-Barrier Penetration (BBB): | 0.259 | Plasma Protein Binding (PPB): | 63.47% |
Volume Distribution (VD): | 0.449 | Fu: | 34.18% |
CYP1A2-inhibitor: | 0.003 | CYP1A2-substrate: | 0.936 |
CYP2C19-inhibitor: | 0.015 | CYP2C19-substrate: | 0.4 |
CYP2C9-inhibitor: | 0.012 | CYP2C9-substrate: | 0.024 |
CYP2D6-inhibitor: | 0.002 | CYP2D6-substrate: | 0.09 |
CYP3A4-inhibitor: | 0.869 | CYP3A4-substrate: | 0.295 |
Clearance (CL): | 4.986 | Half-life (T1/2): | 0.211 |
hERG Blockers: | 0.062 | Human Hepatotoxicity (H-HT): | 0.79 |
Drug-inuced Liver Injury (DILI): | 0.134 | AMES Toxicity: | 0.015 |
Rat Oral Acute Toxicity: | 0.967 | Maximum Recommended Daily Dose: | 0.916 |
Skin Sensitization: | 0.059 | Carcinogencity: | 0.654 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.007 |
Respiratory Toxicity: | 0.981 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003107 | 0.619 | D02JNM | 0.262 | ||||
ENC004027 | 0.328 | D0P0HT | 0.254 | ||||
ENC005525 | 0.309 | D08PIQ | 0.252 | ||||
ENC002216 | 0.293 | D0Y2YP | 0.250 | ||||
ENC003567 | 0.289 | D02QJH | 0.247 | ||||
ENC003564 | 0.285 | D0V9DZ | 0.243 | ||||
ENC002056 | 0.284 | D0Q4SD | 0.242 | ||||
ENC000143 | 0.271 | D06IIB | 0.242 | ||||
ENC003376 | 0.264 | D03BLF | 0.239 | ||||
ENC005965 | 0.258 | D07DVK | 0.239 |